The immunologic aspects of poxvirus oncolytic therapy

Andrea Worschech, D. Haddad, D. F. Stroncek, E. Wang, Francesco M. Marincola, Aladar A. Szalay

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The concept of using replicating oncolytic viruses in cancer therapy dates to the beginning of the twentieth century. However, in the last few years, an increasing number of pre-clinical and clinical trials have been carried out with promising preliminarily results. Novel, indeed, is the suggestion that viral oncolytic therapy might not operate exclusively through an oncolysis-mediated process but additionally requires the "assistance" of the host's immune system. Originally, the host's immune response was believed to play a predominant obstructive role against viral replication, hence limiting the anti-tumor efficacy of viral vectors. Recent data, however, suggest that the immune response may also play a key role in promoting tumor destruction in association with the oncolytic process. In fact, immune effector pathways activated during oncolytic virus-induced tumor rejection seem to follow a similar pattern to those observed when the broader phenomenon of immune-mediated tissue-specific rejection occurs in other immune-related pathologies. We recently formulated the "Immunologic Constant of Rejection" hypothesis, emphasizing commonalties in transcriptional patterns observed when tissue-destruction occurs: whether with a favorable outcome, such as in tumor rejection and pathogen clearance; or a destructive one, such as in allograft rejection or autoimmunity. Here, we propose that a similar mechanism induces clearance of virally infected tumors and that such a mechanism is primarily dependent on innate immune functions.

Original languageEnglish
Pages (from-to)1355-1362
Number of pages8
JournalCancer Immunology, Immunotherapy
Volume58
Issue number9
DOIs
Publication statusPublished - Sep 2009
Externally publishedYes

Fingerprint

Poxviridae
Oncolytic Viruses
Neoplasms
Therapeutics
Autoimmunity
Allografts
Immune System
Clinical Trials
Pathology

Keywords

  • Innate immunity
  • Oncolytic therapy
  • Tumor rejection
  • Vaccinia virus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Worschech, A., Haddad, D., Stroncek, D. F., Wang, E., Marincola, F. M., & Szalay, A. A. (2009). The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunology, Immunotherapy, 58(9), 1355-1362. https://doi.org/10.1007/s00262-009-0686-7

The immunologic aspects of poxvirus oncolytic therapy. / Worschech, Andrea; Haddad, D.; Stroncek, D. F.; Wang, E.; Marincola, Francesco M.; Szalay, Aladar A.

In: Cancer Immunology, Immunotherapy, Vol. 58, No. 9, 09.2009, p. 1355-1362.

Research output: Contribution to journalReview article

Worschech, A, Haddad, D, Stroncek, DF, Wang, E, Marincola, FM & Szalay, AA 2009, 'The immunologic aspects of poxvirus oncolytic therapy', Cancer Immunology, Immunotherapy, vol. 58, no. 9, pp. 1355-1362. https://doi.org/10.1007/s00262-009-0686-7
Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM, Szalay AA. The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunology, Immunotherapy. 2009 Sep;58(9):1355-1362. https://doi.org/10.1007/s00262-009-0686-7
Worschech, Andrea ; Haddad, D. ; Stroncek, D. F. ; Wang, E. ; Marincola, Francesco M. ; Szalay, Aladar A. / The immunologic aspects of poxvirus oncolytic therapy. In: Cancer Immunology, Immunotherapy. 2009 ; Vol. 58, No. 9. pp. 1355-1362.
@article{15a25c1eccd9470e9e06b4b2d83068f6,
title = "The immunologic aspects of poxvirus oncolytic therapy",
abstract = "The concept of using replicating oncolytic viruses in cancer therapy dates to the beginning of the twentieth century. However, in the last few years, an increasing number of pre-clinical and clinical trials have been carried out with promising preliminarily results. Novel, indeed, is the suggestion that viral oncolytic therapy might not operate exclusively through an oncolysis-mediated process but additionally requires the {"}assistance{"} of the host's immune system. Originally, the host's immune response was believed to play a predominant obstructive role against viral replication, hence limiting the anti-tumor efficacy of viral vectors. Recent data, however, suggest that the immune response may also play a key role in promoting tumor destruction in association with the oncolytic process. In fact, immune effector pathways activated during oncolytic virus-induced tumor rejection seem to follow a similar pattern to those observed when the broader phenomenon of immune-mediated tissue-specific rejection occurs in other immune-related pathologies. We recently formulated the {"}Immunologic Constant of Rejection{"} hypothesis, emphasizing commonalties in transcriptional patterns observed when tissue-destruction occurs: whether with a favorable outcome, such as in tumor rejection and pathogen clearance; or a destructive one, such as in allograft rejection or autoimmunity. Here, we propose that a similar mechanism induces clearance of virally infected tumors and that such a mechanism is primarily dependent on innate immune functions.",
keywords = "Innate immunity, Oncolytic therapy, Tumor rejection, Vaccinia virus",
author = "Andrea Worschech and D. Haddad and Stroncek, {D. F.} and E. Wang and Marincola, {Francesco M.} and Szalay, {Aladar A.}",
year = "2009",
month = "9",
doi = "10.1007/s00262-009-0686-7",
language = "English",
volume = "58",
pages = "1355--1362",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "9",

}

TY - JOUR

T1 - The immunologic aspects of poxvirus oncolytic therapy

AU - Worschech, Andrea

AU - Haddad, D.

AU - Stroncek, D. F.

AU - Wang, E.

AU - Marincola, Francesco M.

AU - Szalay, Aladar A.

PY - 2009/9

Y1 - 2009/9

N2 - The concept of using replicating oncolytic viruses in cancer therapy dates to the beginning of the twentieth century. However, in the last few years, an increasing number of pre-clinical and clinical trials have been carried out with promising preliminarily results. Novel, indeed, is the suggestion that viral oncolytic therapy might not operate exclusively through an oncolysis-mediated process but additionally requires the "assistance" of the host's immune system. Originally, the host's immune response was believed to play a predominant obstructive role against viral replication, hence limiting the anti-tumor efficacy of viral vectors. Recent data, however, suggest that the immune response may also play a key role in promoting tumor destruction in association with the oncolytic process. In fact, immune effector pathways activated during oncolytic virus-induced tumor rejection seem to follow a similar pattern to those observed when the broader phenomenon of immune-mediated tissue-specific rejection occurs in other immune-related pathologies. We recently formulated the "Immunologic Constant of Rejection" hypothesis, emphasizing commonalties in transcriptional patterns observed when tissue-destruction occurs: whether with a favorable outcome, such as in tumor rejection and pathogen clearance; or a destructive one, such as in allograft rejection or autoimmunity. Here, we propose that a similar mechanism induces clearance of virally infected tumors and that such a mechanism is primarily dependent on innate immune functions.

AB - The concept of using replicating oncolytic viruses in cancer therapy dates to the beginning of the twentieth century. However, in the last few years, an increasing number of pre-clinical and clinical trials have been carried out with promising preliminarily results. Novel, indeed, is the suggestion that viral oncolytic therapy might not operate exclusively through an oncolysis-mediated process but additionally requires the "assistance" of the host's immune system. Originally, the host's immune response was believed to play a predominant obstructive role against viral replication, hence limiting the anti-tumor efficacy of viral vectors. Recent data, however, suggest that the immune response may also play a key role in promoting tumor destruction in association with the oncolytic process. In fact, immune effector pathways activated during oncolytic virus-induced tumor rejection seem to follow a similar pattern to those observed when the broader phenomenon of immune-mediated tissue-specific rejection occurs in other immune-related pathologies. We recently formulated the "Immunologic Constant of Rejection" hypothesis, emphasizing commonalties in transcriptional patterns observed when tissue-destruction occurs: whether with a favorable outcome, such as in tumor rejection and pathogen clearance; or a destructive one, such as in allograft rejection or autoimmunity. Here, we propose that a similar mechanism induces clearance of virally infected tumors and that such a mechanism is primarily dependent on innate immune functions.

KW - Innate immunity

KW - Oncolytic therapy

KW - Tumor rejection

KW - Vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=67649669811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649669811&partnerID=8YFLogxK

U2 - 10.1007/s00262-009-0686-7

DO - 10.1007/s00262-009-0686-7

M3 - Review article

VL - 58

SP - 1355

EP - 1362

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 9

ER -